Generics and Pharmaceuticals

///Generics and Pharmaceuticals

Everyone Wants Pharmaceutical Breakthroughs. What Drives Drug Companies to Pursue Them?

When choosing which new products to develop, companies must decide how much they want to innovate. Should they make an incremental improvement on an existing product? Or should they create something entirely new? Dimitris Papanikolaou, a professor of finance at Kellogg, explored how this choice plays out in the pharmaceutical industry. Some researchers argue that

2018-09-13T08:01:19+00:00

The New Nonprofit Pharmaceutical World: What’s Up with That?

Two new nonprofit pharmaceutical companies, Civica Rx and Harm Reduction Therapeutics, have declared they want to help patients see more money in their pockets by manufacturing low-cost generic drugs. With public trust in for-profit pharmas at an all-time low, especially when it comes to their relationships with a special brand of self-serving philanthropy, they’d better

2018-09-13T07:49:36+00:00 Tags: |

Hospitals Prepare To Launch Their Own Drug Company To Fight High Prices And Shortages

Sometimes IV bags are hard for hospitals to come by. Other times it's injectable folic acid to treat anemias. Right now, the tissue-numbing agent lidocaine is in short supply. Shortages of commonplace generic drugs have plagued hospitals in recent years. And with short supplies and fewer suppliers for key drugs, there have been price increases. Hospital purchasing agents keep

8,000 new antibiotic combinations are surprisingly effective

Scientists have traditionally believed that combining more than two drugs to fight harmful bacteria would yield diminishing returns. The prevailing theory is that that the incremental benefits of combining three or more drugs would be too small to matter, or that the interactions among the drugs would cause their benefits to cancel one another out.

2018-09-05T07:15:22+00:00 Tags: |

Working group may vet plan to check fake drugs

NEW DELHI: India’s central drug regulator is creating a working group to critically appraise its proposal to set up a “trace and track” mechanism to weed out fake medicines from the market using unique codes. The working group, comprising pharmaceutical association representatives and members of the Central Drugs Standard Control Organisation, is to submit its

2018-08-21T08:28:29+00:00 Tags: |

FDA Approves Teva’s Generic Version of Mylan’s EpiPen

Israel’s Teva Pharmaceuticals shares rallied after the U.S. Food and Drug Administration approved Thursday the company’s generic version of the best-selling, lifesaving allergy injection EpiPen. Although Teva didn’t say when it would begin sales of its product or its price, the approval promises to turn the company into a champion for the millions of Americans who use

It’s Generics Not PBMs That Keep Pharmaceuticals Affordable

Expenditures on prescription drugs grew 12.4 percent in 2014 and 8.9 percent in 2015. These eye-popping data are not representative of the long-term expenditure trend, however. Not only did the growth in prescription drugs expenditures slow to 1.3 percent in 2016, longer-term (between 2009 and 2016), the average annual growth in pharmaceutical expenditures was 3.8

Intermountain to fight pharmaceutical monopolies

As Dan Liljenquist watched former Turing Pharmaceuticals CEO Martin Shkreli raise a rarely-heard-of-drug more than 550%, he had the same thought as nearly everyone else in America: Is this really happening? But unlike most Americans, Liljenquist happens to be in a position to do something about it. The former Utah state senator and the vice president of

Price competition for generic drugs linked to increase in manufacturing-related recalls

Researchers from three universities have found that extreme price competition in the generic pharmaceutical market -- designed to make medications more affordable -- may be putting more patients at serious health risk, as evidenced by a higher number of product recalls caused by manufacturing-related problems. The same research, published online today in the Journal of

2018-06-09T08:07:00+00:00 Tags: |

Most popular vitamin and mineral supplements provide no health benefit, study finds

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital and the University of Toronto. Published today in the Journal of the American College of Cardiology, the systematic review of existing data and single randomized control trials published in

2018-05-30T08:33:07+00:00 Tags: |

Do generic drugs compromise on quality?

You've no doubt seen them in the grocery store — typically drab-looking packages on the bottom shelf containing lower-priced generic versions of popular brand-name products. Some shoppers look at them with skepticism: Are they really as good? Or does cheaper just mean lower quality? Many people have the same questions about generic prescription medications, says

2018-05-29T08:03:45+00:00 Tags: |

Nonprofit Manufacturer Could Keep Generic Drug Costs Down

HealthDay News — A nonprofit manufacturer could help keep generic drug prices down and maintain their supply, according to a perspective piece published in the issue of the New England Journal of Medicine. Dan Liljenquist, J.D., from Intermountain Healthcare in Salt Lake City, and colleagues discuss generic drug market failure, whereby a generic drug manufacturer

2018-05-24T04:56:59+00:00 Tags: |

How to free Indians from the medical poverty trap

India is the largest supplier of generic drugs in the world, and Indian pharmaceutical companies have famously succeeded in pushing down the cost of medication in many countries across the world. Yet, too many Indian citizens do not get access to medicines owing to high costs. The preferred solution of the government right now—price control—is

2018-05-14T07:40:17+00:00 Tags: |

How this pharma executive retired to help people around the world

I am a veteran of Big Pharma. I spent 11 years at Abbott Labs ABT, +1.12% and 16 years at Bristol-Myers BMY, +0.24%  I also spent two years as a pharmaceutical consultant. For almost three decades, I saw annual sales charts that showed the hot spots for pharmaceutical sales. Currently more than 90% of drugs are sold in developed countries and

Who’s investing in health care R&D?

A recent Brookings research report found that the private sector—including pharmaceutical companies, venture capital firms, and impact investors—devotes at least $159.9 billion to investments related to health care research and development (R&D) annually. Though many organizations and publications have measured public sector spending on drugs, vaccines, and therapeutics, the Brookings report is the first to quantify the

New affordable hepatitis C combination treatment shows 97 percent cure rate

An affordable hepatitis C combination treatment including the new drug candidate ravidasvir has been shown to be safe and effective, with extremely high cure rates for patients, including hard-to-treat cases, according to interim results from the Phase II/III STORM-C-1 trial presented by the non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) at

2018-04-24T07:01:19+00:00 Tags: |

Why We May Lose Generic Drugs

The mood at the annual generic drug industry confab in Orlando in February was especially somber. The discussion during one panel was all about plunging drug prices, consolidation among drug-buying groups, and the increasingly cutthroat nature of the business. A top executive at Israel-based Teva Pharmaceutical Industries Ltd., the No. 1 supplier of generics in the U.S.,

Antiepileptic drugs increase risk of Alzheimer’s and dementia

The use of antiepileptic drugs is associated with an increased risk of Alzheimer's disease and dementia, according to a new study from the University of Eastern Finland and the German Center for Neurodegenerative Diseases, DZNE. Continuous use of antiepileptic drugs for a period exceeding one year was associated with a 15 percent increased risk of

2018-04-10T08:03:49+00:00 Tags: |

‘Coffee filter’ helps make new cancer drug Z-endoxifen 1000 times cheaper

Making drugs cheaper doesn’t always require pricey investments. A joint initiative by researchers from TU Eindhoven, the Dutch company Syncom BV and the Antoni van Leeuwenhoek hospital proves just that. What started out as a Bachelor project at TU/e laid the foundation for a much cheaper production of the promising cancer drug Z-endoxifen. Tamoxifen is

2018-04-07T09:19:19+00:00 Tags: |